Post-operatived colon cancer
Conditions
Interventions
Intervation design Xeloda application using group: 10 cases Chemotherapy with Capecitabine(1000mg/m2/day 1-14days), Oxaliplatin(130mg/m2/day day1),every triweekly Intervation period: 6 months
Sponsors
Division of Gastroenterology and hepatology, Department of Internal Medcine, Faculty of Medcine, Toho University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Case requiring postoperative adjuvant chemotherapy after resection of colon cancer 2. Performance Status (ECOG) 0-1 3. Sufficient oral intake 4. Adequate organ functions: WBC >=3500/mm3 and <=12000/mm3, neutrophils >=2000/mm3, platelets >=100,000/mm3, hemoglobin >=9.0g/dL, total bilirubin <=1.5mg/dL, AST(GOT)/ALT(GPT) within twice the normal upper limits
Exclusion criteria
Exclusion criteria: 1. patient who has drug allergy as past history 2. patient who needs flucytosine, phenytoin, and Warfarin 3. patient who has active infectious disease with fever over 38 degree 4. patient who has severe complication (interstitial pneumonia, DM, renal failure, liver failure under bad control) 5. watery diarrhea 6. Pleural effusion and acites 7. patient who has heart disease(CHF, old MI, IHD, arrhythmia, and a valvular disease of the heart) 8.Uncontrolable hypertention 9. patient who want to be pregnant and /or pregnant woman 10. man who want to have a child 11. patient who was judged to be unsuitable for this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Emotional disorder evaluation | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event Dose intensity | — |
Countries
Japan
Contacts
Public ContactYoshinori Kikuchi
Faculty of Medcine, Toho University Division of Gastroenterology and hepatology
Outcome results
None listed